Patisiran (developed by Alnylam with a trading name Onpattro, Cambridge, MA, United state) was the first siRNA used for the treatment of hereditary transthyretin (hATTR) amyloidosis using LNP-based siRNA drug, approved by the U.S. Food and Drug Administration in 2018. The gene discussed is TTR; the disease is amyloidosis.